What is the standard of care for early stage Ovarian Cancer according to NCCN guidelines

Standard of Care for Early-Stage Ovarian Cancer (NCCN Guidelines)

Looking at the NCCN Guidelines for Ovarian Cancer, the standard of care for early-stage disease involves a combination of surgery and, in many cases, chemotherapy. Let me break down what this means:

PRIMARY TREATMENT: SURGERY FIRST

For Stage IA or IB disease: According to NCCN Guidelines, the initial approach depends on whether you want to preserve fertility:

• If fertility preservation is desired: Unilateral salpingo-oophorectomy (USO) — removal of one ovary and fallopian tube — plus comprehensive surgical staging, but only for select cases (Stage IA and IC, but NOT Stage IB)
• If fertility is not a concern: Bilateral salpingo-oophorectomy (BSO) — removal of both ovaries and fallopian tubes — plus comprehensive surgical staging

For Stage IC (high-grade serous or grade 2/3 endometrioid):

• Hysterectomy with BSO plus comprehensive surgical staging and debulking as needed

CHEMOTHERAPY DECISIONS

After surgery, the NCCN Guidelines recommend:

• Stage IA or IB: Either observation OR intravenous (IV) platinum-based chemotherapy (the choice depends on specific risk factors your doctor will evaluate)
• Stage IC (high-grade): IV platinum-based chemotherapy is typically recommended

WHY COMPREHENSIVE SURGICAL STAGING MATTERS

The NCCN Guidelines emphasize that a gynecologic oncologist should perform the primary surgery. This is important because proper staging helps determine:

• Whether chemotherapy is needed
• What type of chemotherapy regimen is best
• Your overall prognosis and follow-up plan

Comprehensive staging includes examining lymph nodes, the omentum (fatty tissue in the abdomen), and peritoneal surfaces to ensure the cancer hasn't spread beyond what imaging shows.

MOLECULAR TESTING

According to NCCN Guidelines, you should also have:

• BRCA1/2 genetic testing (germline and somatic) — this informs future maintenance therapy options if needed
• Homologous recombination deficiency (HRD) testing — may provide information about PARP inhibitor benefit

KEY QUESTIONS TO ASK YOUR ONCOLOGIST

1. What is my exact stage and grade? (This determines treatment intensity)
2. Am I a candidate for fertility-preserving surgery, and do I want to pursue this?
3. Based on my pathology, do I need chemotherapy after surgery, or can I be observed?
4. Have my BRCA and HRD status been tested? (Important for future treatment planning)
5. What is the plan for long-term follow-up and monitoring?

IMPORTANT CONTEXT

The NCCN Guidelines note that early-stage ovarian cancer has different treatment needs than advanced disease. Your specific treatment plan depends on:

• Exact stage and grade of your cancer
• Histologic type (serous, endometrioid, clear cell, etc.)
• Your age and overall health
• Your fertility desires
• Molecular testing results

According to NCCN Guidelines, most patients with epithelial ovarian cancer receive postoperative systemic chemotherapy, but the decision should be individualized based on risk factors your gynecologic oncologist will assess.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.